A big STEP for treatment of heart failure with preserved ejection fraction.
other
Where this comes from
- Record sourced from PubMed, PMID 37643614.
- Also identified by DOI 10.1016/j.cmet.2023.08.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.
Medical subject headings
- Heart Failure
- Stroke Volume